Wide Ranks

FLGT

Fulgent Genetics, Inc.

18.07

Top Statistics
Market Cap 552 M Forward PE -38.95 Revenue Growth -15.30 %
Current Ratio 4.41 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -59.39 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -5.69 Enterprise / Revenue 1.25 Price To Sales Trailing12 Months 1.99
Profitability
Profit Margins -59.39 % Operating Margins -23.81 %
Balance Sheet
Total Cash 213 M Total Cash Per Share 6.97 Total Debt 9 M
Total Debt To Equity 0.8760 Current Ratio 4.41 Book Value Per Share 37.28
All Measures
Short Ratio 264.00 % Message Board Id finmb_315621345 Fax 626 454 1667
Shares Short Prior Month 676102 Return On Equity -0.1435 City El Monte
Uuid 32ef4e17-830f-3fca-bfab-78b786b069a6 Previous Close 17.89 First Trade Date Epoch Utc 1 B
Book Value 37.28 Beta 1.51 Total Debt 9 M
Volume 151563 Price To Book 0.4847 Fifty Two Week Low 16.56
Total Cash Per Share 6.97 Total Revenue 277 M Shares Short Previous Month Date 1 B
Target Median Price 27.00 Audit Risk 4 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -23.81 % Target Mean Price 27.67
Net Income To Common -164968992 Short Percent Of Float 0.0338 Implied Shares Outstanding 30 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 282560
Average Volume10days 282560 Total Cash 213 M Next Fiscal Year End 1 B
Revenue Per Share 9.26 Held Percent Insiders 0.3234 Ebitda Margins -21.89 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 4 Regular Market Previous Close 17.89 Target Low Price 26.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 19.95 Open 18.03
Free Cashflow -35431752 State CA Dividend Yield 0.00 %
Return On Assets -0.0415 Time Zone Short Name EST Board Risk 8
Trailing Eps -5.52 Day Low 18.02 Address1 4399 Santa Anita Avenue
Shares Outstanding 30 M Compensation Risk 7 Price Hint 2
Target High Price 30.00 Website https://www.fulgentgenetics.com 52 Week Change -0.3448
Average Volume 181757 Forward Eps -0.5100 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 375.70 % Is_sp_500 False
Regular Market Day High 18.63 Profit Margins -59.39 % Debt To Equity 0.8760
Fifty Two Week High 30.68 Day High 18.63 Shares Short 579045
Regular Market Open 18.03 Industry Key diagnostics-research Earnings Growth 0.00 %
Enterprise To Revenue 1.25 Revenue Growth -15.30 % Shares Percent Shares Out 0.0189
Operating Cashflow 10 M Currency USD Time Zone Full Name America/New_York
Market Cap 552 M Is_nasdaq_100 False Zip 91731
Quote Type EQUITY Industry Diagnostics & Research Long Name Fulgent Genetics, Inc.
Overall Risk 6 Regular Market Day Low 18.02 Held Percent Institutions 0.5429
Current Price 18.07 Enterprise To Ebitda -5.69 Financial Currency USD
Current Ratio 4.41 Gross Margins 36.22 % Industry Disp Diagnostics & Research
Number Of Analyst Opinions 3 Country United States Float Shares 20 M
Two Hundred Day Average 21.46 Governance Epoch Date 1 B Enterprise Value 346 M
Price To Sales Trailing12 Months 1.99 Forward PE -38.95 Regular Market Volume 151563
Ebitda -60801000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.

The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.

Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs.

The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA.

It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients.

The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016.

Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.